Karen Holzberger, President & CEO, SpinTech MRI | LSI USA '22 Emerging Medtech Summit
Summary
TLDRKaren Holzberger, newly appointed CEO of Spintek MRI, introduces the company as a software platform enhancing MRI data for neurology. Dr. Heike, founder and CSO, is a pioneer in MRI sequences for Parkinson's and dementia. Spintek's solution streamlines MRI data extraction, aiding in early diagnosis and treatment planning. With FDA approval since 2021, Spintek aims to expand its market presence, currently raising Series A funding of $6.5 million, focusing on the US and China's growing neurology market.
Takeaways
- 🌟 Karen Holzberger is the newly appointed CEO and President of Spintek MRI.
- 🧠 Spintek MRI is a software platform that enhances the MRI ecosystem by providing data outputs to care teams for better decision-making in brain health.
- 👨⚕️ Dr. Heike is the Chief Scientific Officer and founder of Spintek MRI, known for inventing MRI sequences used in neurology.
- 📈 The company aims to address the global prevalence of neurological disorders, such as Parkinson's and dementia, which are difficult to diagnose early.
- 🏥 MRI is a critical diagnostic tool for neurological disorders, but there are challenges with the efficiency and effectiveness of its use in healthcare systems.
- 🚀 Spintek's software operates as an MRI software platform, aiming to improve diagnostic efficiency without compromising the quality of imaging data.
- 🌐 Spintek's solution is comprehensive and works across the MRI ecosystem, regardless of the MRI system used, providing interoperability.
- 💉 The company is FDA approved since October 2021 and is working on expanding its market presence, especially in the United States and China.
- 💼 Spintek is currently raising Series A funding, with a commitment of $6.5 million, $5 million of which has already been committed.
- 🌐 The company's global market priorities include improving patient outcomes, financial outcomes, and clinical outcomes in neurology.
Q & A
Who is Karen Holzberger?
-Karen Holzberger is the newly appointed CEO and President of Spintek MRI.
What is Spintek MRI?
-Spintek MRI is a software platform that operates across the MRI ecosystem to extract and deliver imaging data outputs to care teams for better-informed decisions regarding brain health.
Who is Dr. Heike?
-Dr. Heike is the Chief Scientific Officer and founder of Spintek MRI. He is recognized for inventing many MRI sequences used in neurology for diagnosing and treating diseases like Parkinson's and dementia.
What are some of Dr. Heike's accomplishments?
-Dr. Heike has over 300 research papers and nearly 20 patents, focusing on neurological disorders and MRI technology.
What challenges is Spintek MRI addressing?
-Spintek MRI is addressing the challenges of diagnosing and treating neurological disorders like Parkinson's disease, which is difficult to identify within the first five years and often misdiagnosed.
How does Spintek MRI's software help with MRI scans?
-Spintek MRI's software allows for efficient extraction and curation of imaging data without compromising sequence time or patient time in the MRI machine.
What is the significance of being FDA approved for Spintek MRI?
-Being FDA approved since October 2021 allows Spintek MRI to market their solutions in the United States and assures the quality and safety of their software platform.
What is Spintek MRI's Series A funding goal?
-Spintek MRI is closing their Series A funding with a commitment of six and a half million dollars, with five million already committed.
What are Spintek MRI's priorities in the global market?
-Their priorities include expanding their solutions in the United States, addressing the specific needs of the Chinese market, and continuing to grow their presence in the global MRI market.
How does Spintek MRI plan to expand its services?
-Spintek MRI plans to expand into neck and spine imaging, potentially using MRI data outputs for musculoskeletal applications, and to continue developing their software platform.
What partnerships does Spintek MRI have?
-Spintek MRI has partnerships with Siemens and GE Healthcare, as well as with Octave in the diagnostics and bioscience space.
What are some of the institutions working with Spintek MRI?
-Spintek MRI is working with institutions like Yale University, University of Maryland, and Loma Linda, among others.
Outlines
🧠 Spintek MRI's Vision and Mission
Karen Holzberger introduces herself as the new CEO and President of Spintek MRI, a software platform that enhances the MRI ecosystem for better brain health decisions. She highlights the company's collaboration with Dr. Heike, the Chief Scientific Officer, who is a pioneer in MRI sequences used for diagnosing neurological disorders like Parkinson's and dementia. The script discusses the global prevalence of such disorders and the challenges in their early diagnosis and treatment. It emphasizes the importance of MRI as a diagnostic tool and how Spintek's software can efficiently provide data outputs to care teams without compromising the scanning time, thus aiding in early and accurate diagnosis.
🌐 Global Market Priorities and Expansion
The second paragraph delves into Spintek MRI's global market strategy, with a focus on the United States and China. It discusses the urgency of efficient MRI scanning, especially in China where time constraints are stringent. The company's goal is to reduce scan time while maintaining comprehensive diagnostic information. Holzberger outlines the company's ambition to expand its software's applicability across different body regions and disease states, not just in neurology but also in musculoskeletal (MSK) imaging. She mentions partnerships with industry leaders like Siemens and GE Healthcare and ongoing pilots with academic institutions. The script concludes with an update on the company's Series A funding, which aims to bring Dr. Heike's research to market and address significant challenges in brain health and neurology.
Mindmap
Keywords
💡Spintek MRI
💡MRI
💡Neurological disorders
💡Dr. Heike
💡Parkinson's disease
💡Dementia
💡Neurology
💡Interoperability
💡FDA approval
💡Series A funding
💡Health systems
Highlights
Karen Holzberger is the newly appointed CEO and President of Spintek MRI.
Spintek MRI is a software platform that works across the MRI ecosystem to improve brain health decisions.
Dr. Heike is the Chief Scientific Officer and founder, recognized for inventing MRI sequences used in neurology.
Dr. Heike has contributed over 300 research papers and nearly 20 patents in the field of neurology.
Spintek MRI aims to tackle the prevalence of neurological disorders and improve diagnosis and treatment.
10 million patients are diagnosed with Parkinson's each year, highlighting the need for better diagnostic tools.
Spintek's software operates as an MRI software platform to aid neurologists in disease detection.
The MRI is a powerful diagnostic tool for neurological diseases, but there are tensions in its efficiency.
Spintek has developed a solution to extract and curate MRI data efficiently without compromising sequence time.
The company's Stage solution is a comprehensive brain imaging tool aimed at improving patient outcomes.
Spintek's software is interoperable across different MRI systems, including those from Philips, GE, and Siemens.
Spintek is FDA approved since October 2021.
The company is currently in Series A funding, with a commitment of $6.5 million.
Spintek's priorities include expanding in the US and China, focusing on neurology and potentially into neck and spine.
The company has partnerships with Siemens, GE Healthcare, and Octave in diagnostics and bioscience.
Karen Holzberger has been in radiology and enterprise imaging for 20 years and is committed to solving brain health issues.
Spintek is finalizing Series A funding to bring Dr. Heike's research to market and address neurological challenges.
Transcripts
hello again i'm karen holzberger i'm the
newly appointed ceo and president of
spintek mri um let me get the clicker
here
um with that who who are we um we're a
software platform that works across the
mri ecosystem that extracts and brings
data outputs imaging data outputs to the
care teams to make better informed
decisions around brain health
and i'm really excited to be at the helm
with dr hakey dr heike is our chief
scientific officer and founder he is
well recognized in the in the world of
mri
really as the inventor of many of the
sequences that doctors and providers are
using today to really start to indicate
and treat diseases around parkinson's
dementia other movement disorders all
around neurology it's incredible what
he's done over the past 40 years with
300 plus research
papers done around these disease states
as well as 19 and almost 20 patents and
it's really excited to bring his
lifelong work
to to market you know across the globe
and the mri ecosystem
let's talk a little bit about like the
problems and things that we're tackling
if you think about the prevalence of
neurological disorders across the globe
and how they're treated each year 10
million patients are diagnosed with
parkinson's and to give you that example
it's a really difficult
disease to start treating within the
first five years as well as identifying
there's no single clinical test there's
many different treatment options
and incredibly enough
three out of four times they're only
getting the answer correct
and when they start doing this they
start in imaging and this is where we
play a role as being the software
operating system over the mri a
neurologist a primary care physician the
first indication around many of these
diseases to order an mri
and you can see what can happen the mri
is an extraordinarily powerful tool
diagnostic tool and the go-to tool for
these doctors to make these informed
decisions and start to develop these
care treatment plans
there's this tension happening within
the health system that you hear about
all the time the tension to keep these
machines running as effectively and
efficiently as possible
the neurologists are looking for these
data outputs but they come at a cost and
a trade-off to each other you have about
10 minutes to run some of these brain
images to get the data output that you
need the quantitative and qualitative
output of these micro bleeds these very
small nuances found in the imaging you
need to take longer time and what we've
we've been able to develop through dr
hakey's work and our company spintec is
to be able to extract curate and put
together in an output
efficiently effectively without
compromising the sequence time or how
long that patient's in the machine
really important as the departments the
health systems who are you know seeing
so many patients each and every day
whether it's inpatient in the afternoon
the ambulatory patients during the day
to be able to keep these machines
running as efficiently and effectively
as possible and imbalance giving the
information to the neurologist to make
informed earlier diagnosis with the
tools that we're giving them with the
imaging data
and so this is where stage comes in we
are a comprehensive brain imaging
solution
really thinking about and across the
care pathways that we talked about to
really help give the doctors the right
tools early to make these diagnoses to
improve patient outcomes the financial
outcomes as well as the clinical
outcomes um
you know for our health systems and
what's interesting about this is that
because we work across the mri ecosystem
and what does that mean well it doesn't
matter what mr the systems are using
whether it's in china where there's 6
000 high field magnets today in the u.s
where there's 8 000 magnets today
whether it's from philips ge siemens
united
that we've got this ability and the
interoperability to be able to extract
this data and give that information to
the doctor so they can make the right
informed choices i'm excited to say that
we are fda approved and we've been fda
approved since october of 2021
we've been working with key partners
here and i talked a little bit about the
market here what's happening but with
that where we are
to be able to actually
really kind of put the demand to this
market our priority today with the
funding that we've received we're in our
series a just closing that out a
commitment of six and a half million
five million has been committed already
but to really start what is happening in
the united states around mr how do we
start taking our solutions putting in
the hands of the neurologist our second
priority alcohol horizon two is really
what we have to do in china again as i
said they're six thousand high field mr
the pressures that the chinese face is
around how much time do they have to
scan their patients their revelants
around parkinson's disease they allow
four to five minutes per scan and we
have the ability to give them to take 40
of the time off that scan but still give
them the comprehensive information
around these disease states these
movement disorders these brain diseases
for that so you can see the priorities
that we have in the global market that
continues to grow at three to six
percent kgar every year
really incredible time for us to be to
be able to extract this information
and give it into the hands of the
doctors because well the other problem
that's happening is many of these
diseases are have a disconnection to how
they're treated
whether it's in the early stage in the
diagnosis and the identification of
parkinson's or other brain disorders
other movement disorders to the ongoing
treatment
because for example when i talk about
this for the u.s
typically a parkinson's patient is
imaged four times per year on mri so
what else can we do to continue to
provide that longitudinal record of the
imaging data as the brain is kind of you
know continuing to transform in the
information that those neurologists need
and what's interesting for us as i said
you know we hit our first fda of the
stage platform for here focusing on
neuro our ambitions are continuing to
get to our we have a sas based model
today but continuing to get into public
cloud we also know as we go across the
horizontals of the disease state and
neurology we also know that if we can we
will continue into neck and spine
which gives us opportunity to use um mr
and getting the data outputs for
msk or musculoskeletal and continuing to
go across whether it's the body region
or the disease states as well as the
infra the the regions around the world
because what's interesting is the fact
that
you know mr is again the de facto tool
it's a very powerful diagnostic tool the
tensions that happen between of getting
the data having the time to get the data
that we are able to do that too because
of our interoperability so it's really
exciting um we get our net our next
product called crown through fda
approval hopefully by the end of the
year that's our goal which then opens up
the market for us not just for the high
field magnets but the 1.5 team magnets
too so it's a really exciting time for
us and so where are we today so we've
got partnerships with siemens and ge
healthcare as well as in the diagnostics
and bioscience space with octave
who is really tackling the ecosystem
around multiple sclerosis and
parkinson's you know we see ourselves
being the imaging data output and
reporting for the neurologist for this
our thought leaders and continued early
pilots being yale
um university of maryland as well as
loma linda you know in the work that
we're doing at university of michigan
it's really a terrific time for us
and then finally like i had said um
we're even though i'm like very early
stage in my role here as a ceo we're
finalizing our series a funding at six
and a half million dollars five has been
committed um which really we will focus
on you know taking dr hakey's you know
research and software platform and
really bringing it to market to solve
some of the most challenging problems
that we see today
around brain health and neurology it's
my personal mission i didn't really tell
you a little bit by myself but i've been
in
radiology and enterprise imaging for the
past 20 years and to be a part of what
dr hakey's been doing
to really solve these issues and solve
these you know these chronic diseases to
make it a little bit better and hearing
yesterday last night's discussion
around you know american cancer society
and what we can do to help not the
patients today but the patients of
tomorrow with this so thank you very
much for the time i appreciate it and
have a wonderful conference
[Applause]
Weitere ähnliche Videos ansehen
MRI and CT Scan the differences
MRI Physics Fourier Transform for MRI Kucharczyk
Is PSA Density Still Relevant? #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
MRI physics overview | MRI Physics Course | Radiology Physics Course #1
Wie funktioniert MRT? T1 und T2 Wichtung
Brain MRI scan protocols, positioning and planning
5.0 / 5 (0 votes)